Systematizing PDE4 Inhibition in Psoriasis Treatment: Roflumilast Leads the Way
Remya Ravindran1★, Palayyan Muralidharan2★, Arulkumaran Govindarajan3★ Corresponding author
- 1Department of Pharmaceutics, Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamil Nadu, INDIA.
- 2Department of Pharmacology, Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamil Nadu, INDIA.
- 3Department of Pharmaceutics, KTN College of Pharmacy, Palakkad, Kerala, INDIA.
CORRESPONDENCE
Remya Ravindran
Department of Pharmaceutics, Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamil Nadu, INDIA.
Received: 27-09-2024; Revised: 04-10-2024; Accepted: 08-11-2024.
Volume 17, Issue 1 · pp. 13–18 · PUBLISHED · DOI: 10.5530/jyp.20251506
ABSTRACT
Psoriasis, a prevalent autoimmune disorder, presents significant challenges due to its chronic inflammatory nature and multifactorial etiology, involving both genetic tendency and environmental factors. Conventional therapies, while providing symptomatic relief, often stay behind to achieve sustained remission. This review explores advancements in psoriasis treatment, emphasizing the emergence of targeted therapies and biologics as the priority in enhancing disease management. Focus is on plaque psoriasis, the most common clinical subtype and the role of Roflumilast, a Phosphodiesterase-4 (PDE4) inhibitor, in modern therapeutic approaches. Roflumilast exerts immunomodulatory effects by increasing intracellular cyclic Adenosine Monophosphate (cAMP), which attenuates inflammation and keratinocyte hyperproliferation, key pathological features of psoriasis. A comprehensive literature review was conducted using scholarly databases and clinical trial registries. Key terms such as “Psoriasis treatment,” “PDE4 inhibitors,” “Roflumilast,” “Targeted therapy,” and “Therapeutic efficacy” guided the search. Priority was given to randomized controlled trials, observational studies and meta-analyses to ensure robust data inclusion. Clinical evidence suggests that Roflumilast exhibits a favorable safety profile compared to conventional treatments. Highlighting findings include rapid clinical improvement, patients achieving clear or almost clear skin within weeks and fewer adverse effects, indicating its efficacy and tolerability. This review brings to light Roflumilast’s potential to revolutionize psoriasis treatment, offering improved outcomes and safety. While additional research is inevitable to establish its long-term safety profile, Roflumilast represents a promising step forward in enhancing patient quality of life and reshaping psoriasis management.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Ravindran, R., Muralidharan, P., & Govindarajan, A. (). Systematizing PDE4 Inhibition in Psoriasis Treatment: Roflumilast Leads the Way. Journal of Young Pharmacists, 17(1), 13–18. https://doi.org/10.5530/jyp.20251506